• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

单链DNA结合因子SUB1/PC4可缓解端粒处的复制应激,是替代延长途径(ALT)癌细胞的一个脆弱点。

The single-stranded DNA-binding factor SUB1/PC4 alleviates replication stress at telomeres and is a vulnerability of ALT cancer cells.

作者信息

Dubois Jean-Christophe, Bonnell Erin, Filion Amélie, Frion Julie, Zimmer Samuel, Riaz Khan Muhammad, Teplitz Gabriela M, Casimir Lisa, Méthot Élie, Marois Isabelle, Idrissou Mouhamed, Jacques Pierre-Étienne, Wellinger Raymund J, Maréchal Alexandre

机构信息

Département de Biologie, Université de Sherbrooke, Sherbrooke, QC J1K 2R1, Canada.

Cancer Research Institute, Université de Sherbrooke, Sherbrooke, QC J1K2R1, Canada.

出版信息

Proc Natl Acad Sci U S A. 2025 Jan 14;122(2):e2419712122. doi: 10.1073/pnas.2419712122. Epub 2025 Jan 7.

DOI:10.1073/pnas.2419712122
PMID:39772744
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11745411/
Abstract

To achieve replicative immortality, cancer cells must activate telomere maintenance mechanisms. In 10 to 15% of cancers, this is enabled by recombination-based alternative lengthening of telomeres pathways (ALT). ALT cells display several hallmarks including heterogeneous telomere length, extrachromosomal telomeric repeats, and ALT-associated PML bodies. ALT cells also have high telomeric replication stress (RS) enhanced by fork-stalling structures (R-loops and G4s) and altered chromatin states. In ALT cells, telomeric RS promotes telomere elongation but above a certain threshold becomes detrimental to cell survival. Manipulating RS at telomeres has thus been proposed as a therapeutic strategy against ALT cancers. Through analysis of genome-wide CRISPR fitness screens, we identified ALT-specific vulnerabilities and describe here our characterization of the roles of SUB1, a ssDNA-binding protein, in telomere stability. SUB1 depletion increases RS at ALT telomeres, profoundly impairing ALT cell growth without impacting telomerase-positive cells. During RS, SUB1 is recruited to stalled forks and ALT telomeres via its ssDNA-binding domain. This recruitment is potentiated by RPA depletion, suggesting that these factors may compete for ssDNA. The viability of ALT cells and their resilience toward RS also requires ssDNA binding by SUB1. SUB1 depletion accelerates cell death induced by FANCM depletion, triggering unsustainable levels of telomeric damage in ALT cells. Finally, combining SUB1 depletion with RS-inducing drugs rapidly induces replication catastrophe in ALT cells. Altogether, our work identifies SUB1 as an ALT susceptibility with roles in the mitigation of RS at ALT telomeres and suggests advanced therapeutic strategies for a host of still poorly managed cancers.

摘要

为实现复制永生,癌细胞必须激活端粒维持机制。在10%至15%的癌症中,这是通过基于重组的端粒替代延长途径(ALT)实现的。ALT细胞表现出几个特征,包括端粒长度不均一、染色体外端粒重复序列以及ALT相关的PML小体。ALT细胞还具有由叉停滞结构(R环和G4s)和改变的染色质状态增强的高端粒复制应激(RS)。在ALT细胞中,端粒RS促进端粒延长,但超过一定阈值就会对细胞存活有害。因此,有人提出操纵端粒处的RS作为针对ALT癌症的治疗策略。通过对全基因组CRISPR适应性筛选的分析,我们确定了ALT特异性的脆弱性,并在此描述我们对单链DNA结合蛋白SUB1在端粒稳定性中作用的表征。SUB1缺失会增加ALT端粒处的RS,严重损害ALT细胞生长,而不影响端粒酶阳性细胞。在RS期间,SUB1通过其单链DNA结合结构域被招募到停滞的叉和ALT端粒。RPA缺失会增强这种招募,表明这些因子可能竞争单链DNA。ALT细胞的活力及其对RS的恢复力也需要SUB1结合单链DNA。SUB1缺失会加速由FANCM缺失诱导的细胞死亡,在ALT细胞中引发不可持续的端粒损伤水平。最后,将SUB1缺失与RS诱导药物联合使用会迅速在ALT细胞中诱导复制灾难。总之,我们的工作确定SUB1是一种ALT易感性因素,在减轻ALT端粒处的RS方面发挥作用,并为许多仍难以治疗的癌症提出了先进的治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/ad4bb0b8173f/pnas.2419712122fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/60b16ec88bd9/pnas.2419712122fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/c96359314d94/pnas.2419712122fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/40842c02aedf/pnas.2419712122fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/8b9024c8ff62/pnas.2419712122fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/6bd2b94e331d/pnas.2419712122fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/ad4bb0b8173f/pnas.2419712122fig06.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/60b16ec88bd9/pnas.2419712122fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/c96359314d94/pnas.2419712122fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/40842c02aedf/pnas.2419712122fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/8b9024c8ff62/pnas.2419712122fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/6bd2b94e331d/pnas.2419712122fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9d5f/11745411/ad4bb0b8173f/pnas.2419712122fig06.jpg

相似文献

1
The single-stranded DNA-binding factor SUB1/PC4 alleviates replication stress at telomeres and is a vulnerability of ALT cancer cells.单链DNA结合因子SUB1/PC4可缓解端粒处的复制应激,是替代延长途径(ALT)癌细胞的一个脆弱点。
Proc Natl Acad Sci U S A. 2025 Jan 14;122(2):e2419712122. doi: 10.1073/pnas.2419712122. Epub 2025 Jan 7.
2
SLX4IP acts in parallel to FANCM to limit BLM-dependent replication stress at ALT telomeres.SLX4IP与FANCM协同作用,以限制ALT端粒处依赖BLM的复制应激。
bioRxiv. 2025 May 29:2025.05.28.656696. doi: 10.1101/2025.05.28.656696.
3
Comparison of Telomere Structure in Eukaryotes.真核生物中端粒结构的比较。
Arch Razi Inst. 2024 Dec 31;79(6):1365-1374. doi: 10.32592/ARI.2024.79.6.1365. eCollection 2024 Dec.
4
Human PC4 supports telomere stability and viability in cells utilizing the alternative lengthening of telomeres mechanism.人类PC4通过端粒延长替代机制维持细胞中端粒的稳定性和细胞活力。
EMBO Rep. 2024 Dec;25(12):5294-5315. doi: 10.1038/s44319-024-00295-3. Epub 2024 Oct 28.
5
Telomere Length and Telomerase Activity as Biomarkers in the Diagnostics and Prognostics of Pathological Conditions.端粒长度和端粒酶活性作为病理状况诊断和预后的生物标志物
Biochemistry (Mosc). 2025 Jun;90(6):700-724. doi: 10.1134/S0006297925600814.
6
Dyskeratosis Congenita and Related Telomere Biology Disorders先天性角化不良及相关端粒生物学障碍
7
A First-in-Class High-Throughput Screen to Discover Modulators of the Alternative Lengthening of Telomeres (ALT) Pathway.一种用于发现端粒替代延长(ALT)途径调节剂的首创高通量筛选方法。
ACS Pharmacol Transl Sci. 2024 Aug 13;7(9):2799-2819. doi: 10.1021/acsptsci.4c00251. eCollection 2024 Sep 13.
8
Management of urinary stones by experts in stone disease (ESD 2025).结石病专家对尿路结石的管理(2025年结石病专家共识)
Arch Ital Urol Androl. 2025 Jun 30;97(2):14085. doi: 10.4081/aiua.2025.14085.
9
Novel role for Ddx39 in differentiation and telomere length regulation of embryonic stem cells.Ddx39 在胚胎干细胞分化和端粒长度调控中的新作用。
Cell Death Differ. 2024 Nov;31(11):1534-1544. doi: 10.1038/s41418-024-01354-x. Epub 2024 Aug 6.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.

本文引用的文献

1
Replication-induced DNA secondary structures drive fork uncoupling and breakage.复制诱导的 DNA 二级结构导致叉解偶联和断裂。
EMBO J. 2023 Nov 15;42(22):e114334. doi: 10.15252/embj.2023114334. Epub 2023 Oct 2.
2
Highlighting vulnerabilities in the alternative lengthening of telomeres pathway.突出端粒的非经典延长途径中的脆弱性。
Curr Opin Pharmacol. 2023 Jun;70:102380. doi: 10.1016/j.coph.2023.102380. Epub 2023 May 5.
3
RPA engages telomeric G-quadruplexes more effectively than CST.RPA 比 CST 更有效地结合端粒 G-四链体。
Nucleic Acids Res. 2023 Jun 9;51(10):5073-5086. doi: 10.1093/nar/gkad315.
4
Homology directed telomere clustering, ultrabright telomere formation and nuclear envelope rupture in cells lacking TRF2 and RAP1.缺乏 TRF2 和 RAP1 的细胞中同源定向端粒聚类、超强端粒形成和核膜破裂。
Nat Commun. 2023 Apr 14;14(1):2144. doi: 10.1038/s41467-023-37761-w.
5
TERRA and RAD51AP1 promote alternative lengthening of telomeres through an R- to D-loop switch.TERRA 和 RAD51AP1 通过 R 环到 D 环转换促进端粒的替代性延长。
Mol Cell. 2022 Nov 3;82(21):3985-4000.e4. doi: 10.1016/j.molcel.2022.09.026. Epub 2022 Oct 19.
6
The alternative lengthening of telomeres mechanism jeopardizes telomere integrity if not properly restricted.端粒的非经典延长机制如果得不到适当的限制,会危及端粒的完整性。
Proc Natl Acad Sci U S A. 2022 Sep 27;119(39):e2208669119. doi: 10.1073/pnas.2208669119. Epub 2022 Sep 19.
7
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT.TOP3A 扩增和 ATRX 失活在使用 ALT 的儿童骨肉瘤中是相互排斥的事件。
EMBO Mol Med. 2022 Oct 10;14(10):e15859. doi: 10.15252/emmm.202215859. Epub 2022 Aug 3.
8
Guiding ATR and PARP inhibitor combinationswith chemogenomic screens.指导 ATR 和 PARP 抑制剂组合与化学生物基因组筛选。
Cell Rep. 2022 Jul 12;40(2):111081. doi: 10.1016/j.celrep.2022.111081.
9
Targeting telomeres: advances in telomere maintenance mechanism-specific cancer therapies.靶向端粒:端粒维持机制特异性癌症治疗的进展。
Nat Rev Cancer. 2022 Sep;22(9):515-532. doi: 10.1038/s41568-022-00490-1. Epub 2022 Jul 5.
10
New twists to the ALTernative endings at telomeres.端粒处 ALT 端的新转折。
DNA Repair (Amst). 2022 Jul;115:103342. doi: 10.1016/j.dnarep.2022.103342. Epub 2022 May 13.